Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Verve Therapeutics' most advanced new treatment candidate, VERVE-101, produced positive results in its first clinical trial. Inexperienced biotechnology investors were dealt a painful lesson, ...

What if a heart attack and lifetime of statin drugs could be avoided with a one-time, two-hour infusion? Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...

Verve Therapeutics (NASDAQ: VERV) is up 16.5% for the week. The biotech stock, which was as low as $41.52 a share on Monday, climbed as high as $48.39 by Thursday. For a relatively new stock (it ...

Since reporting some early-stage clinical data from one of its gene editing programs on Nov. 12, share prices of Verve Therapeutics (VERV-2.29%) are down 42%. But contrary to what you may be ...

Clinical testing of a Verve Therapeutics genetic medicine addressing an inherited form of high cholesterol is ongoing in the U.K. and New Zealand, but plans for a U.S. clinical trial have hit a ...

Verve Therapeutics, Inc. (NASDAQ:VERV) is a Boston, Mass., based biotech that IPO'd in June 2021, raising ~$307m via the issuance of 16.1m shares priced at $19 per share.

Why Verve Therapeutics stock tanked. There were no issues on the safety front that clearly indicate trouble ahead for VERVE-101 but the initial portion of the study was less than flawless.